Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis?

Abstract

Neutralising antibodies (NAbs) against interferon (IFN)-β reduce the treatment effect in multiple sclerosis (MS). However, data from pivotal trials of IFN-β in MS suggest that NAb-positive patients may have a reduced relapse rate during the first six to 12 months of therapy. We collected clinical data and plasma samples for NAb measurements prospectively, every six months, in 468 patients treated with the same IFN-β preparation for at least 24 months. NAbs were measured blindly with a cytopathic effect (CPE) assay. During treatment months 0-6, patients who became NAb-positive had significantly fewer relapses compared to patients who maintained the NAb-negative status, whereas the opposite was observed after month 6. This is in accordance with observations in randomised studies of the three different IFN-β preparations, showing that patients who become NAb-positive have lower relapse rates during the first six or 12 months of therapy. We hypothesise that low affinity NAbs, present early after the start of IFN-β therapy, though neutralising in vitro in sensitive assays increase the half-life of IFN-β in vivo and, thereby, enhance the therapeutic effect. With affinity maturation, NAbs effectively prevent IFN-β binding to its receptors also in vivo and, hence, abolish the treatment effect. Multiple Sclerosis 2007; 13: 616-621. http://msj.sagepub.com

Keywords

binding antibodies interferon-beta multiple sclerosis neutralising antibodies therapy treatment effect

Get full access to this article

View all access options for this article.

References

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interfleron beta-1a flor disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.

Panitch H. , Goodin DS , Francis G. , Chang P. , Coyle PK , O'Connor P. et al. Randomized, comparative study ofl interfleron beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-506.

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study ofl interfleron beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.

Ross C. , Clemmesen KM , Svenson M. , Sorensen PS , Koch-Henriksen N. , Skovgaard GL et al. Immunogenicity ofl interfleron-beta in multiple sclerosis patients: influence ofl preparation, dosage, dose flrequency, and route ofl administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706-12.

The IFNB Multiple Sclerosis Study Group. Interfleron beta-1b is eflflective in relapsing-remitting multiple sclerosis. I. Clinical results ofl a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.

Sorensen PS , Deisenhammer F. , Duda P. , Hohlfeld R. , Myhr KM , Palace J. et al. Guidelines on use ofl antiinterfleron-beta antibody measurements in multiple sclerosis - report ofl an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-27.

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment ofl multiple sclerosis with interfleron beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.

Bertolotto A. , Deisenhammer F. , Gallo P. , Solberg SP Immunogenicity ofl interfleron beta: diflflerences among products. J Neurol 2004; 251: 1115-24.

Francis GS , Rice GP , Alsop JC Interfleron beta-1a in MS: results flollowing development ofl neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55.

10.

Kappos L. , Clanet M. , Sandberg-Wollheim M. , Radue EW , Hartung HP , Hohlfeld R. et al. Neutralizing antibodies and eflficacy ofl interfleron beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.

11.

Polman C. , Kappos L. , White R. , Dahlke F. , Beckmann K. , Pozzilli C. et al. Neutralizing antibodies during treatment ofl secondary progressive MS with interfleron beta-1b. Neurology 2003 ; 60: 37-43.

12.

Sorensen PS , Ross C. , Clemmesen KM , Bendtzen K. , Frederiksen JL , Jensen K. et al. Clinical importance ofl neutralising antibodies against interfleron beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.

13.

European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multi-centre randomised trial ofl interfleron beta-1b in treatment ofl secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.

14.

PRISMS Study Group.

PRISMS-4: long-term eflficacy ofl interfleron-beta-1a in relapsing

MS. Neurology 2001; 56: 1628-36.

15.

Koch-Henriksen N. , Sorensen PS The Danish National Project ofl interfleron-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. Mult Scler 2000; 6: 172-75.

16.

Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61: S6-S10.

17.

Ross C. , Svenson M. , Clemmesen KM , Sorensen PS , Koch-Henriksen N. , Bendtzen K. Measuring and evaluating interfleron-beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39-46.

18.

Petkau AJ , White RA , Ebers GC , Reder AT , Sibley WA , Lublin FD et al. Longitudinal analyses ofl the eflflects ofl neutralizing antibodies on interfleron beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-38.

19.

Clanet M. , Radue EW , Kappos L. , Hartung HP , Hohlfeld R. , Sandberg-Wollheim M. et al. A randomized, double-blind, dose-comparison study ofl weekly interfleron beta-1a in relapsing MS. Neurology 2002; 59: 1507-17.

20.

Clanet M. , Kappos L. , Hartung HP , Hohlfeld R. Interfleron beta-1a in relapsing multiple sclerosis: flouryear extension ofl the European IFNbeta-1a dose-comparison Study. Mult Scler 2004; 10: 139-44.

21.

Brickelmaier M. , Hochman PS , Baciu R. , Chao B. , Cuervo JH , Whitty A. ELISA methods flor the analysis ofl antibody responses induced in multiple sclerosis patients treated with recombinant interfleron-beta. J Immunol Methods 1999; 227: 121-35.

22.

Bendtzen K. , Svenson M. , Jonsson V. , Hippe E.

Autoantibodies to cytokines - flriends or floes?

Immunol Today 1990; 11: 167-69.

23.

Gneiss C. , Tripp P. , Ehling R. , Khalil M. , Lutterotti A. , Egg R. et al. Interfleron-beta antibodies have a higher aflfinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies . J Neuroimmunol 2006; 174: 174-79.

24.

May LT , Neta R. , Moldawer LL , Kenney JS , Patel K. , Sehgal PB Antibodies chaperone circulating IL-6. Paradoxical eflflects ofl anti-IL-6 `neutralizing' antibodies in vivo. J Immunol 1993;151: 3225-36.